Monopar Therapeutics (MNPR) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for August 5, 2024, with four key proposals for shareholder vote, including director elections, auditor ratification, a reverse stock split, and an amendment to the stock incentive plan.

• Board unanimously recommends voting in favor of all proposals and nominees.

• Only shareholders of record as of July 12, 2024, are eligible to vote.

Voting matters and shareholder proposals

• Six current directors are nominated for re-election to serve until the next annual meeting.

• Proposal to ratify BPM LLP as independent auditor for 2024.

• Proposal to approve a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the Board's discretion, to maintain Nasdaq listing.

• Proposal to amend the 2016 Stock Incentive Plan, increasing shares available for awards by 2,000,000.

• No other business or director nominees are expected at the meeting.

Board of directors and corporate governance

• Board consists of six members, with four deemed independent under Nasdaq standards.

• Board committees include Audit, Compensation, Corporate Governance & Nominating, and Plan Administrator Committees.

• All directors attended at least 75% of meetings in 2023; all attended the last annual meeting.

• Board diversity matrix provided, showing gender and ethnic composition.